Dendrocalamus latiflorus and its component rutin exhibit glucose-lowering activities by inhibiting hepatic glucose production via AKT activation.
10.1016/j.apsb.2021.11.017
- Author:
Kun LUO
1
;
Wenting HUANG
1
;
Liansheng QIAO
1
;
Xiaoling ZHANG
2
;
Di YAN
3
;
Zhiyu NING
1
;
Chengmei MA
2
;
Honglei DANG
2
;
Dong WANG
3
;
Hongyan GUO
2
;
Lan XIE
1
;
Jing CHENG
1
Author Information
1. State Key Laboratory of Membrane Biology, School of Medicine, Tsinghua University, Beijing 100084, China.
2. National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China.
3. School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Publication Type:Journal Article
- Keywords:
AKT;
DLE, Dendrocalamus latiflorus leaf extract;
Dendrocalamus latiflorus leaf extract;
FOXO1;
FOXO1, forkhead box O1;
G6PC, glucose 6 phosphatase;
Gene expression profiling;
IGF1R;
IGF1R, insulin growth factor 1 receptor;
Network pharmacology;
PCK1, phosphoenolpyruvate carboxykinase 1;
PIN, protein interaction network;
PKB/AKT, protein kinase B;
Rutin;
T2DM, type 2 diabetes mellitus;
Type 2 diabetes mellitus
- From:
Acta Pharmaceutica Sinica B
2022;12(5):2239-2251
- CountryChina
- Language:English
-
Abstract:
The potential medicinal value of Ma bamboo (Dendrocalamus latiflorus), one of the most popular and economically important bamboo species in China, has been underestimated. In the present study, we found that D. latiflorus leaf extract (DLE) reduced fasting blood glucose levels, body weight, and low-density lipoprotein cholesterol with low liver toxicity in db/db mice. In addition, gene expression profiling was performed and pathway enrichment analysis showed that DLE affected metabolic pathways. Importantly, DLE activated the AKT signaling pathway and reduced glucose production by downregulating glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase 1 (PCK1) expression. Moreover, network pharmacology analysis identified rutin as an active component in DLE through targeting insulin growth factor 1 receptor (IGF1R), an upstream signaling transducer of AKT. Due to its hypoglycemic effects and low toxicity, DLE may be considered an adjuvant treatment option for type 2 diabetes patients.
